Rituximab
Showing 1 - 25 of 2,343
Rituximab in Children With Blood Diseases
Not yet recruiting
- Rituximab
- +2 more
- Rituximab
- Rituximab (once a week)
- (no location specified)
Apr 8, 2022
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)
Recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Rituximab
- Zanubrutinib
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 26, 2022
Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,
Recruiting
- Burkitt Lymphoma
- +2 more
- Rituximab and Hyaluronidase Human
- +8 more
-
Kampala, UgandaUCI-Fred Hutch Cancer Centre
Mar 9, 2022
Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 20, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
-
Scottsdale, Arizona
- +11 more
Aug 23, 2022
Prognostic Model of Rituximab in the Treatment of MN
Not yet recruiting
- Idiopathic Membranous Nephropathy
- Rituximab
- (no location specified)
Dec 28, 2022
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma
Not yet recruiting
- Double-Expressor Lymphoma
- +3 more
- Cyclophosphamide
- +6 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 27, 2022
Pharmacological Action Trial (Rituximab, Dexamethasone)
Not yet recruiting
- Pharmacological Action
- Rituximab
- Dexamethasone
- (no location specified)
Sep 22, 2022
CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)
Active, not recruiting
- CCND1 Positive
- +6 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 11, 2022
Waldenstrom Macroglobulinemia Trial (Venetoclax; Rituximab, DRC)
Not yet recruiting
- Waldenstrom Macroglobulinemia
- Venetoclax; Rituximab
- DRC
- (no location specified)
Jul 27, 2022
Idiopathic Membranous Nephropathy Trial (Rituximab, Cyclophosphamide)
Not yet recruiting
- Idiopathic Membranous Nephropathy
- Rituximab
- Cyclophosphamide
- (no location specified)
Aug 22, 2022
Untreated Mantle Cell Lymphoma Trial in Suzhou (zanubrutinib and rituximab, BEAM pretreatment, zanubrutinib maintenance)
Recruiting
- Untreated Mantle Cell Lymphoma
- zanubrutinib and rituximab
- +2 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Aug 16, 2022
Refractory Myasthenia Gravis, Rituximab Trial in Guangzhou (Rituximab)
Recruiting
- Refractory Myasthenia Gravis
- Rituximab
- Rituximab
-
Guangzhou, ChinaFirst Affiliated Hospital, Sun Yat-Sen University
Apr 26, 2022
Nefopam Trial (Nefopam ampule, diphenhydramine ampule)
Not yet recruiting
- Nefopam
- Nefopam ampule
- diphenhydramine ampule
- (no location specified)
Dec 13, 2022
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Apr 4, 2022
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial
Active, not recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +9 more
- Ibrutinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Feb 3, 2022
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1
Active, not recruiting
- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- +9 more
- Quality-of-Life Assessment
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Feb 3, 2022
Steroid-Dependent Nephrotic Syndrome Trial in Kolkata (Rituximab, Mycophenolate Mofetil)
Active, not recruiting
- Steroid-Dependent Nephrotic Syndrome
- Rituximab
- Mycophenolate Mofetil
-
Kolkata, West Bengal, IndiaNilratan Sircar Medical College and Hospital
Apr 6, 2022
Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Tafasitamab
- +3 more
-
Cologne, GermanyUniversity of Cologne
Oct 14, 2022
Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Chimeric Antigen Receptor T-Cell Therapy
- +3 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Mar 8, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial (Nemtabrutinib, Fludarabine, Cyclophosphamide)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Leukemia
- Nemtabrutinib
- +7 more
- (no location specified)
Nov 30, 2022
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)
Not yet recruiting
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Bone Marrow Aspiration and Biopsy
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022